In the cloned rat thymic endocrine epithelial cell line TEA3A 1, treatment with dexamethasone leads to decreased levels of prostaglandin E2, prostaglandin F2a, and thromboxane B2. Dexamethasone treatment also leads to a decrease of both calcium-dependent and calcium-independent phospholipase A2 activity measured in a cell-free assay. Dexamethasone-treated cells also have increased levels of lipocortin-I, a putative modulator of phospholipase A2 activity. The property of calcium-dependent binding of lipocortin to the particulate fraction was used to prepare cytosolic and particulate subcellular fractions which contained phospholipase A2 activity but no lipocortin-I. Dexamethasone decreased phospholipase A2 activity in both cytosolic and particulate fractions even in the absence of lipocortin, suggesting the presence of a lipocortin-independent mechanism.
INTRODUCTION
Arachidonic acid metabolites are known to be potent modulators of T cell growth and function [1] [2] [3] . Prosta- glandins are also believed to play an important role in T cell development in the thymus [4] [5] [6] . The fact that prostaglandin levels in the thymus are 4-10-fold higher than in plasma [4, 7] also suggests the importance of prostaglandins in thymic function.
Thymic epithelial cells have been postulated to play an important role in regulating thymic prostaglandin levels [8] . Recently, we have cloned a rat thymic epithelial cell line, TEA3AL. TEA3A1 cells synthesize the thymic hormone thymosine a, as well as expressing a marker for endocrine thymic epithelium [9] . We are using the cell line as an experimental model to study regulation of arachidonate metabolism.
In this paper we examine some aspects of regulation by glucocorticoids. Glucocorticoid is a known inhibitor of arachidonate release in other cell types and tissues [10, 11] , and has been reported to inhibit release of prostaglandin E2 (PGE2) and prostaglandin F2l (PGF2z) by primary cultures containing predominantly thymic epithelial cells [12, 13] . This effect of glucocorticoids has been shown (in other tissues) to require protein synthesis, and has been presumed to be mediated by the induction and secretion of phospholipase A2 (PLA2) inhibitory proteins known as lipocortins [10, 11] . Included in this family are wellcharacterized intracellular proteins which are tyrosine kinase substrates, lipocortin-I and lipocortin-II [14] . Lipocortin-I has been found in high concentrations in thymic epithelium and in TEA3AI cells [15] . However, the involvement of intracellular lipocortin-I and related proteins as mediators of glucocorticoid inhibition of arachidonate release is still open to question. It has been shown recently that in a cell-free assay system used to measure PLA2 inhibition, lipocortins act by binding to the substrate rather than by directly inhibiting the enzyme [16, 17] .
The current study finds that glucocorticoid inhibits prostaglandin production by TEA3Al cells and also raises the level of lipocortin-I. We also show the novel finding that glucocorticoid decreases the level of PLA2 activity in a cell-free assay, and that this effect is independent of lipocortin-I.
MATERIALS AND METHODS Materials
All radiolabelled substrates were purchased from New England Nuclear Research Products (Boston, MA, U.S.A.). Unlabelled L-a-palmitoyl-2-oleoyl lecithin was obtained from Avanti Polar Lipids (Birmingham, AL, U.S.A.). Calcium-free WAJC 404 medium was generously supplied by Kyokuto Pharmaceutical Co., Ltd. (Tokyo, Japan). The composition of this medium has been described by McKeehan et al. [18] . Preparation and characterization of specific antiserum to lipocortin-I (35 kDa epidermal growth factor receptor substrate) has been reported [19, 20] . Cell culture Culture and maintenance of the rat endocrine thymic epithelial cell line (TEA3A1) has been described in detail [9] . Stock cultures are grown and passaged in WAJC 404A medium (7.5 % DMEM in calcium-free WAJC 404) supplemented with 10 ,ug of insulin/ml, 10 ,tg of transferrin/ml, 10 ,#M-dexamethasone, 10 I To whom all correspondence should be addressed.
Vol. 261 sCS. Dexamethasone was added to cultures either at the beginning or at various times before performing assays. Enzyme assays Confluent TEA3A1 cultures (dexamethasone-treated and controls) were washed with phosphate-buffered saline (PBS; 137 mM-NaCl/3 mM-KCl/8 mM-Na2 HPO4/ 1.5 mM-KH2PO4), then scraped into assay buffer containing 10 mM-Tris (pH 7.5), 2 mM-EDTA, aprotinin (1 ,tg/ml), pepstatin (1 ,ug/ml) and leupeptin (1 jg/ml). The cell suspension was sonicated briefly. In some experiments the cell lysate was separated into supernatant and pellet fractions by centrifugation at 100000 g for 45 min with or without added 2 mM-free calcium. The amount of protein in each sample was determined by a modified Lowry assay [22] . One unit of PLA2 activity is defined as the release of 1 nmol of free fatty acid/h from the exogenous substrate.
Preliminary experiments established that the rate of hydrolysis of the substrate was proportional to the amount of substrate used (up to 1 mg of protein for a 60 min assay) and linear with respect to time for this period. With the maximal cellular PLA2 activity measured, approx. 300 of the substrate was hydrolysed by 60 min.
Radioimmunoassay of arachidonate metabolites
Media from cells cultured in the presence or absence of dexamethasone were assayed separately for PGE2, PGF2aC and thromboxane B2 (TXB2) by radioimmunoassay, a modification of the procedure described by Campbell & Oieda [23] . Antibody (100,u), 3H-labelled tracer (15000 c.p.m., 25 pg, 100,1l) and the sample to be tested or unlabelled standard (100 ,tl), all in assay buffer (PBS + 0.1 % gelatin) were mixed and incubated overnight at 4 'C. Dextran-charcoal suspension (300 ,ul) was added to remove the unbound antigen, and the mixture was centrifuged. Supernatant (0.5 ml) was added to 5.0 ml of scintillation cocktail and the radioactivity was measured on a scintillation counter. A standard curve was produced for each experiment. The cross-reactivities of the antisera used in these assays has been determined to be less than 0.5 % (radioimmunoassay for PGE, also measures PGA2, a spontaneous derivative of PGE2). 
RESULTS

Effects of dexamethasone on arachidonate metabolism in intact TEA3A1 cells
The levels of several individual arachidonate metabolites released into the medium in response to dexamethasone were determined by radioimmunoassay (Table 1) . It was found the dexamethasone treatment decreased levels of PGE2 (78 %), PGF2a (77 0%) and TXB2 (77 %). The time-course for dexamethasone inhibition of PGE2 production ( Fig. la) shows an effect by 6-12 h which reaches a maximum by 36 h. The doseresponse (Fig. lb) shows that half-maximal inhibition occurs with 10 nM-dexamethasone. Effect of dexamethasone treatment on PLA2 activity
In determining whether or not the effects of dexamethasone on arachidonate metabolism in intact TEA3A1 cells could be correlated with an inhibitory effect on cellular PLA2, we wished to avoid the complication of apparent inhibition which is due to substrate sequestering rather than regulation of enzyme activity (see Introduction). Therefore, we used high concen- [10, 11] , glucocorticoid induction of the intracellular lipocortin-I has not been shown, to our knowledge. Using specific antiserum for lipocortin-I, we were able to demonstrate that TEA3AI cells cultured with dexamethasone do contain higher levels of lipocortin-I as analysed by Western blot (Fig. 2) .
The dexamethasone effect on PLA2 activity in the cellfree enzyme assay is independent of lipocortin Lipocortins I and II and related proteins share the property of calcium-dependent binding to phospholipid [14, 16, 20, 26] . When subcellular fractions are prepared in the presence of calcium, lipocortin is found in the particulate fraction; in the presence of EDTA, lipocortin appears in the soluble fractions [26] . This property has been used in the purification of lipocortin-I [20] and was confirmed here by Western blotting (Fig. 3) . In Table 3 , subcellular fractions prepared in the presence of either free calcium or EDTA were assayed for PLA2 using substrate at 400 /tM concentration. Although specific activities vary between experiments, it can be seen that within each experiment, the dexamethasone effect on PLA2 activity is just as pronounced in cell fractions from which lipocortin was absent (both supernatants and pellets). The lower apparent specific activity in the pellet fractions as compared with supernatants reflects the presence of endogenous phospholipid in the pellet, which would compete with the radiolabelled substrate. 1-3) or same medium plus 100 nM-dexamethasone (lanes 4-6); 10 jtg of total protein per lane. Dexamethasone may affect several distinct phospholipases in TEA3A1 cells Further experiments were carried out to characterize the dexamethasone-sensitive phospholipase activities in both supernatant and pellet fractions as to calcium dependence. Fractions were prepared in the presence of EDTA and were then assayed for PLA2 in the presence or absence of 2 mm excess free calcium (Table 4) . Dexamethasone treatment consistently decreased phospholipase activities in the supernatant assayed in either the presence or absence of calcium. Pellet activity in the presence of calcium was also decreased by dexamethasone. The same effect was seen whether oleic or Table 3 . The effect of dexamethasone on PLA2 activity in the cell-free assay system is independent of the presence of lipocortins TEA3A1 cells were grown to confluence in DW-IT plus 20 Thin-layer chromatographic analysis of the reaction products of sn-2-labelled phosphatidylcholine substrates with TEA3A1 cell lysates (results not shown) indicated the presence of PLA1 activity. Since an alternative pathway of arachidonate production could involve PLA1 plus lysophospholipid lipase, it is possible that dexamethasone could be acting on this pathway instead of on PLA2 as is usually supposed. The use of an sn-I etherlinked phosphatidylcholine substrate, which is resistant to PLA1 hydrolysis, confirmed that dexamethasone treatment decreases PLA2 activity.
Western blotting experiments using antiserum to lipo- was found to decrease PLA2 activity in both supernatant and pellet fractions in the absence of lipocortins. Furthermore, both calcium-dependent and calcium-independent phospholipase activities in the supernatant were decreased by dexamethasone treatment. These results, obtained with a cell-free assay system, do not rule out a role for lipocortins as phospholipase regulators in intact TEA3A1 cells. They do demonstrate, at least, that another mechanism for dexamethasone inhibition of PLA2 activity does exist. The effect of dexamethasone could be due to decreases in the level of the PLA2 enzymes themselves, or could be mediated through other types of regulators which do not have the property of calcium-dependent binding to membranes which is found with lipocortins.
